EA201391797A1 - 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS AGONISTS OF GREELINE RECEPTORS - Google Patents
3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS AGONISTS OF GREELINE RECEPTORSInfo
- Publication number
- EA201391797A1 EA201391797A1 EA201391797A EA201391797A EA201391797A1 EA 201391797 A1 EA201391797 A1 EA 201391797A1 EA 201391797 A EA201391797 A EA 201391797A EA 201391797 A EA201391797 A EA 201391797A EA 201391797 A1 EA201391797 A1 EA 201391797A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- derivatives
- greeline
- agonists
- receptors
- piperidine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Изобретение относится к производным формулы (I), где заместители представляют собой, как определено в описании; к способам получения данных производных; фармацевтическим композициям, содержащим данные производные; данным производным в качестве лекарственного средства; данным производным для лечения расстройства или заболевания, опосредованного грелиновым рецептором.The invention relates to derivatives of formula (I), where the substituents are, as defined in the description; to methods for obtaining these derivatives; pharmaceutical compositions containing these derivatives; given derivatives as a medicine; derivatives for the treatment of a disorder or disease mediated by a ghrelin receptor.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161490848P | 2011-05-27 | 2011-05-27 | |
US201161560960P | 2011-11-17 | 2011-11-17 | |
US201261642116P | 2012-05-03 | 2012-05-03 | |
PCT/IB2012/052649 WO2012164473A1 (en) | 2011-05-27 | 2012-05-25 | 3-spirocyclic piperidine derivatives as ghrelin receptor agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201391797A1 true EA201391797A1 (en) | 2014-04-30 |
Family
ID=46317469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201391797A EA201391797A1 (en) | 2011-05-27 | 2012-05-25 | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS AGONISTS OF GREELINE RECEPTORS |
Country Status (21)
Country | Link |
---|---|
US (2) | US8546416B2 (en) |
EP (1) | EP2714690A1 (en) |
JP (1) | JP2014515369A (en) |
KR (1) | KR20140023399A (en) |
CN (1) | CN103562206A (en) |
AP (1) | AP2013007234A0 (en) |
AR (1) | AR086554A1 (en) |
AU (1) | AU2012264305A1 (en) |
BR (1) | BR112013030391A2 (en) |
CA (1) | CA2835916A1 (en) |
CL (1) | CL2013003211A1 (en) |
CO (1) | CO6811856A2 (en) |
CR (1) | CR20130625A (en) |
EA (1) | EA201391797A1 (en) |
IL (1) | IL229320A0 (en) |
MX (1) | MX355072B (en) |
PE (1) | PE20140610A1 (en) |
SG (1) | SG194616A1 (en) |
TW (1) | TW201302749A (en) |
UY (1) | UY34094A (en) |
WO (1) | WO2012164473A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104271579A (en) * | 2012-05-03 | 2015-01-07 | 诺华股份有限公司 | L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists |
EP2950790A4 (en) | 2012-08-09 | 2018-04-25 | Dynamis Therapeutics, Inc. | Methods for maintaining or improving health, well-being and/or a physiological function in a subject |
AP2016009496A0 (en) | 2014-04-04 | 2016-10-31 | X-Rx Inc | Substituted spirocydic inhibitors of autotaxin |
EP3212648A1 (en) * | 2014-10-31 | 2017-09-06 | RaQualia Pharma Inc. | Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists |
US11202776B2 (en) * | 2017-05-12 | 2021-12-21 | Takeda Pharmaceutical Company Limited | Treatment of gastroparesis with triazaspiro[4.5]decanone |
CN111175387B (en) * | 2018-11-13 | 2022-06-07 | 成都康弘药业集团股份有限公司 | Method for detecting milnacipran isomer |
CN113125583B (en) * | 2019-12-30 | 2022-06-21 | 成都百裕制药股份有限公司 | Method for detecting content of genotoxic impurities in pantoprazole sodium for injection |
US11993600B2 (en) * | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5536716A (en) | 1992-12-11 | 1996-07-16 | Merck & Co., Inc. | Spiro piperidines and homologs which promote release of growth hormone |
RO115804B1 (en) * | 1992-12-11 | 2000-06-30 | Merck & Co Inc | Spiropyperidine derivatives, processes for preparation and pharmaceutical compositions thereof |
EP0828754B1 (en) | 1995-05-29 | 2005-02-02 | Pfizer Inc. | Dipeptides which promote release of growth hormone |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
AU7169696A (en) * | 1995-09-26 | 1997-04-17 | Merck & Co., Inc. | 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone |
AU3220097A (en) | 1996-05-22 | 1997-12-09 | Arch Development Corporation | Sleep quality improvement using a growth hormone secretagogue |
ATE356139T1 (en) * | 1997-06-25 | 2007-03-15 | Pfizer | DIPEPTIDE DERIVATIVES FOR PROMOTING GROWTH HORMONE SECRETION |
UA64751C2 (en) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Treatment of insulin tolerance using substances increasing growth hormone secretion |
TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
US6329342B1 (en) | 1997-08-19 | 2001-12-11 | Eli Lilly And Company | Treatment of congestive heart failure with growth hormone secretagogues |
ZA987385B (en) | 1997-08-19 | 2000-04-18 | Lilly Co Eli | Growth hormone secretagogues. |
GB9802251D0 (en) | 1998-02-03 | 1998-04-01 | Ciba Geigy Ag | Organic compounds |
DE69913548T2 (en) | 1998-10-02 | 2004-09-23 | Novartis Ag | MGLUR5 ANTAGONISTS FOR THE TREATMENT OF PAIN AND ANXIETY |
US6194578B1 (en) | 1998-11-20 | 2001-02-27 | Pfizer Inc. | Dipeptide derivatives |
SI1004583T1 (en) | 1998-11-23 | 2004-12-31 | Pfizer Products Inc. | Process and hydantoin intermediates for the synthesis of growth hormone secretagogues |
GB9913079D0 (en) | 1999-06-04 | 1999-08-04 | Novartis Ag | Organic compounds |
DOP2001000154A (en) | 2000-05-25 | 2002-05-15 | Pfizer Prod Inc | COMBINATION OF SECRETAGOGOS OF HORMONE OF THE GROWTH AND ANTIDEPRESSANTS |
ATE446758T1 (en) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | USE OF GROWTH HORMONE SECRETAGOGENES TO PROMOTE DIGESTIVE MOTILITY |
IL143690A0 (en) | 2000-06-19 | 2002-04-21 | Pfizer Prod Inc | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
GB0028702D0 (en) | 2000-11-24 | 2001-01-10 | Novartis Ag | Organic compounds |
CN1500089A (en) | 2001-03-26 | 2004-05-26 | ��˹��ŵ�� | Fused pyridine derivatives as capsaicin receptor antagonists for the treatment of pain |
CN1268610C (en) | 2001-05-14 | 2006-08-09 | 诺瓦提斯公司 | Sulfonamide derivatives |
JP3894035B2 (en) | 2001-07-04 | 2007-03-14 | 東レ株式会社 | Carbon fiber reinforced substrate, preform and composite material comprising the same |
TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
AU2003218273A1 (en) | 2002-04-10 | 2003-10-27 | Eli Lilly And Company | Stereoselective process for the synthesis of (d)-2-amino-5-phenylpentanoic or alkyl ester thereof |
US6696468B2 (en) | 2002-05-16 | 2004-02-24 | Dainippon Pharmaceutical Co., Ltd. | (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor |
SE0201940D0 (en) | 2002-06-20 | 2002-06-20 | Astrazeneca Ab | New combination II |
DOP2003000703A (en) | 2002-09-20 | 2004-03-31 | Pfizer | IMIDAZOPIRADINE COMPOUNDS AS 5-HT4 RECEIVER AGONISTS |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
PE20040844A1 (en) | 2002-11-26 | 2004-12-30 | Novartis Ag | PHENYLACETIC ACIDS AND DERIVATIVES AS COX-2 INHIBITORS |
GB0302876D0 (en) | 2003-02-07 | 2003-03-12 | Novartis Ag | Organic compounds |
EP1631260A2 (en) | 2003-02-28 | 2006-03-08 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
JP2004277319A (en) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1-(4-piperidinylmethyl)piperidinylamide derivative and medicinal composition containing the same |
JP2004277318A (en) | 2003-03-14 | 2004-10-07 | Dainippon Pharmaceut Co Ltd | 1-(1-substituted carbonyl-4-piperidinylmethyl)piperidine derivative and medicinal composition containing the same |
NZ543482A (en) | 2003-05-21 | 2009-02-28 | Prosidion Ltd | Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phoshorylase |
EP1505064A1 (en) | 2003-08-05 | 2005-02-09 | Bayer HealthCare AG | 2-Aminopyrimidine derivatives |
CA2534785A1 (en) | 2003-08-12 | 2005-02-17 | Robin Douglas Clark | Tetrahydroquinazoline derivatives as cfr antagonists |
CN1835753A (en) | 2003-08-12 | 2006-09-20 | 弗·哈夫曼-拉罗切有限公司 | Spiro tetrahydroquinazolines and dihydrocyclopentapyrimidines as CFR antagonists |
EP1664010A1 (en) | 2003-08-29 | 2006-06-07 | Vernalis (R&D) Limited | Sulfonamides antagonising n-type calcium channels |
JP3983269B1 (en) | 2003-09-03 | 2007-09-26 | ファイザー株式会社 | Benzimidazolone compounds having 5-HT4 receptor agonist activity |
CA2537916A1 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
JP2005082508A (en) | 2003-09-05 | 2005-03-31 | Dainippon Pharmaceut Co Ltd | 2-alkoxy-6-amino-5-halogeno-n-(1-substituted-4-piperidinyl)pyridine-3-carboxamide derivative and pharmaceutical composition containing the same |
CN1878773A (en) | 2003-09-05 | 2006-12-13 | 神经能质公司 | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands |
AU2004272437A1 (en) | 2003-09-09 | 2005-03-24 | Ono Pharmaceutical Co., Ltd. | CRF antagonists and heterobicyclic compounds |
GB0322612D0 (en) | 2003-09-26 | 2003-10-29 | Novartis Ag | Organic compounds |
JP2005104896A (en) | 2003-09-30 | 2005-04-21 | Dainippon Pharmaceut Co Ltd | 2-alkoxy-6-amino-5-halogenopyridine-3-carboxamide derivative and pharmaceutical composition containing the same |
US20050070527A1 (en) | 2003-09-30 | 2005-03-31 | Edwards James P. | Quinoxaline compounds |
BRPI0414918A (en) | 2003-09-30 | 2006-11-07 | Janssen Pharmaceutica Nv | benzoimidazole compounds |
CA2543707A1 (en) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Nitrogen-containing fused heterocyclic compounds |
RU2372339C2 (en) | 2003-11-10 | 2009-11-10 | Мерк Энд Ко., Инк. | Substituted triazoles as sodium channel blockers |
US7208596B2 (en) | 2003-11-25 | 2007-04-24 | Bristol-Myers Squibb Pharma Company | Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof |
WO2005054239A1 (en) | 2003-12-05 | 2005-06-16 | Bayer Healthcare Ag | 2-aminopyrimidine derivatives |
US7211568B2 (en) | 2003-12-18 | 2007-05-01 | Kosan Biosciences Incorporated | 9-Desoxoerythromycin compounds as prokinetic agents |
JP2005206590A (en) | 2003-12-25 | 2005-08-04 | Mitsubishi Pharma Corp | Selective inhibitor of sodium channel site 2 |
ES2344568T3 (en) | 2004-01-07 | 2010-08-31 | Aryx Therapeutics, Inc. | STEREOISOMERAL COMPOUNDS AND METHODS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS AND THE CENTRAL NERVOUS SYSTEM. |
WO2005073222A1 (en) | 2004-01-29 | 2005-08-11 | Pfizer Japan, Inc. | 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity |
TW200533348A (en) | 2004-02-18 | 2005-10-16 | Theravance Inc | Indazole-carboxamide compounds as 5-ht4 receptor agonists |
WO2005092882A1 (en) | 2004-03-01 | 2005-10-06 | Pfizer Japan, Inc. | 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders |
EP1574478A1 (en) | 2004-03-08 | 2005-09-14 | Solvay Fluor GmbH | Preparation of carbonyl difluoride |
WO2005092066A2 (en) | 2004-03-25 | 2005-10-06 | Janssen Pharmaceutica N.V. | Imidazole compounds |
EP1732564A1 (en) | 2004-03-29 | 2006-12-20 | Merck & Co., Inc. | Biaryl substituted pyrazinones as sodium channel blockers |
TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
EP1734820A4 (en) | 2004-04-16 | 2008-01-23 | Neurogen Corp | Imidazopyrazines, imidazopyridines, and imidazopyrimidines as crf1 receptor ligands |
GB0412768D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
GB0412769D0 (en) | 2004-06-08 | 2004-07-07 | Novartis Ag | Organic compounds |
EA200801608A1 (en) | 2004-06-15 | 2008-10-30 | Пфайзер Инк. | DERIVATIVES OF BENZIMIDAZOLONIC CARBONIC ACID |
SE0401653D0 (en) | 2004-06-24 | 2004-06-24 | Astrazeneca Ab | New compounds |
WO2006023757A2 (en) | 2004-08-19 | 2006-03-02 | University Of Virginia Patent Foundation | Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents |
GB0420424D0 (en) | 2004-09-14 | 2004-10-20 | Ionix Pharmaceuticals Ltd | Therapeutic compounds |
WO2006038594A1 (en) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | N-type calcium channel inhibitor |
GB0519957D0 (en) | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
US7396933B2 (en) | 2004-11-05 | 2008-07-08 | Theravance, Inc. | Quinolinone-carboxamide compounds |
WO2006052640A1 (en) | 2004-11-05 | 2006-05-18 | Theravance, Inc. | 5-ht4 receptor agonist compounds |
JP2008519794A (en) | 2004-11-11 | 2008-06-12 | アージェンタ・ディスカバリー・リミテッド | Pyrimidine compounds |
US20060111416A1 (en) | 2004-11-24 | 2006-05-25 | Lane Charlotte A L | Octahydropyrrolo[3,4-C]pyrrole derivatives |
RU2404179C2 (en) | 2004-12-22 | 2010-11-20 | Тереванс, Инк. | Indazole-carboxamide compounds |
EP1818061A1 (en) | 2005-12-02 | 2007-08-15 | Charite-Universitätsmedizin Berlin | Use of ghrelin for stimulating hair growth |
US7601844B2 (en) | 2006-01-27 | 2009-10-13 | Bristol-Myers Squibb Company | Piperidinyl derivatives as modulators of chemokine receptor activity |
JP2010518090A (en) | 2007-02-09 | 2010-05-27 | トランザイム・ファーマ,インコーポレイテッド | Macrocyclic ghrelin receptor modulators and methods of use thereof |
US7994203B2 (en) | 2008-08-06 | 2011-08-09 | Novartis Ag | Organic compounds |
US8273900B2 (en) | 2008-08-07 | 2012-09-25 | Novartis Ag | Organic compounds |
EP2482813A4 (en) | 2009-09-30 | 2013-02-27 | Tranzyme Pharma Inc | Salts, solvates, and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same |
-
2012
- 2012-05-24 UY UY0001034094A patent/UY34094A/en not_active Application Discontinuation
- 2012-05-24 AR ARP120101842A patent/AR086554A1/en unknown
- 2012-05-24 US US13/479,596 patent/US8546416B2/en active Active
- 2012-05-25 MX MX2013013950A patent/MX355072B/en active IP Right Grant
- 2012-05-25 AU AU2012264305A patent/AU2012264305A1/en not_active Abandoned
- 2012-05-25 EA EA201391797A patent/EA201391797A1/en unknown
- 2012-05-25 PE PE2013002562A patent/PE20140610A1/en not_active Application Discontinuation
- 2012-05-25 AP AP2013007234A patent/AP2013007234A0/en unknown
- 2012-05-25 SG SG2013079082A patent/SG194616A1/en unknown
- 2012-05-25 EP EP12727947.9A patent/EP2714690A1/en not_active Withdrawn
- 2012-05-25 WO PCT/IB2012/052649 patent/WO2012164473A1/en active Application Filing
- 2012-05-25 BR BR112013030391A patent/BR112013030391A2/en not_active Application Discontinuation
- 2012-05-25 CA CA2835916A patent/CA2835916A1/en not_active Abandoned
- 2012-05-25 KR KR1020137034118A patent/KR20140023399A/en not_active Application Discontinuation
- 2012-05-25 JP JP2014512000A patent/JP2014515369A/en active Pending
- 2012-05-25 TW TW101118859A patent/TW201302749A/en unknown
- 2012-05-25 CN CN201280025862.9A patent/CN103562206A/en active Pending
-
2013
- 2013-08-08 US US13/962,689 patent/US20130331369A1/en not_active Abandoned
- 2013-11-07 IL IL229320A patent/IL229320A0/en unknown
- 2013-11-08 CL CL2013003211A patent/CL2013003211A1/en unknown
- 2013-11-20 CO CO13273132A patent/CO6811856A2/en active IP Right Grant
- 2013-11-27 CR CR20130625A patent/CR20130625A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20130331369A1 (en) | 2013-12-12 |
JP2014515369A (en) | 2014-06-30 |
IL229320A0 (en) | 2014-01-30 |
PE20140610A1 (en) | 2014-05-31 |
BR112013030391A2 (en) | 2016-12-13 |
WO2012164473A1 (en) | 2012-12-06 |
EP2714690A1 (en) | 2014-04-09 |
MX355072B (en) | 2018-04-04 |
AP2013007234A0 (en) | 2013-11-30 |
CL2013003211A1 (en) | 2014-07-04 |
CN103562206A (en) | 2014-02-05 |
AU2012264305A1 (en) | 2013-11-21 |
SG194616A1 (en) | 2013-12-30 |
CA2835916A1 (en) | 2012-12-06 |
TW201302749A (en) | 2013-01-16 |
MX2013013950A (en) | 2014-01-23 |
CR20130625A (en) | 2014-02-04 |
CO6811856A2 (en) | 2013-12-16 |
US8546416B2 (en) | 2013-10-01 |
US20120302540A1 (en) | 2012-11-29 |
AR086554A1 (en) | 2014-01-08 |
KR20140023399A (en) | 2014-02-26 |
UY34094A (en) | 2013-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201390381A1 (en) | TRIAZINOXADIAZOLES | |
EA201391797A1 (en) | 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS AGONISTS OF GREELINE RECEPTORS | |
CY1118379T1 (en) | DISEASES OF USVITIS C | |
EA201591087A1 (en) | NEW BENZIMIDAZOLE DERIVATIVES AS ANTAGONISTS OF EP4 RECEPTOR | |
EA201501122A1 (en) | NEW AGONISTS OF SOMATOSTATIN RECEPTORS OF SUB-TYPE 4 (SSTR4) | |
EA201290940A1 (en) | NEW CONNECTIONS AS SELECTIVE ANTAGONISTS OF NK3 RECEPTOR, PHARMACEUTICAL COMPOSITION AND METHODS OF THEIR USE FOR DAMAGE MEDIATED BY NK3 RECEPTORS | |
EA201591195A1 (en) | NEW QUINOLON DERIVATIVES | |
CY1116328T1 (en) | Derivative 4 - aminopyrimidine and their use as adenosine A2A receptor antagonists | |
PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
NI201400043A (en) | 4 - PHENYL - PYRIDINES SUBSTITUTED FOR THE TREATMENT OF DISEASES RELATED TO THE NK1 RECEPTOR | |
EA201390969A1 (en) | GLUCAGON RECEPTOR MODULATORS | |
EA201500298A1 (en) | ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES | |
CY1123456T1 (en) | METHOD OF PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROME-4-ONE DERIVATIVES AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL SUBSTANCES | |
EA201492287A1 (en) | DEUTERED DERIVATIVES RUXOLITINIBA | |
EA201492023A1 (en) | REGULATORS OF THE COMPLEX WAY AND THEIR APPLICATION | |
EA201200471A1 (en) | SIMPLE ESSENTIAL DERIVATIVES OF BICYCLIC HETEROARILS | |
MX2016007128A (en) | Ccr6 compounds. | |
PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
EA201300946A1 (en) | ASYMMETRIC UREA AND THEIR MEDICAL APPLICATION | |
EA201391056A1 (en) | Heteroaryl compounds as ligands of the 5-HTRECEPTOR | |
MX360330B (en) | Administration regime for nitrocatechols. | |
CY1116720T1 (en) | 2-AMINO-3- (IMIDAZOL-2-YL) -PYRIDIN-4-ONE PRODUCER AND THEIR USE AS VEGF RECEPTOR MODEL INSPECTORS | |
MX339858B (en) | Novel compounds as histamine h3 receptor ligands. | |
EA201270302A1 (en) | ANHARROUND FORMS OF PYRIDINE DERIVATIVES | |
CR20130318A (en) | NEW BENZODIOXOL-PIPERAZINA COMPOUNDS |